Intercell Announces First Subject Enrolled in a Phase II Trial for the further development of its Vaccine Enhancement Patch
Phase II clinical trial investigating the effectiveness of Intercell’s Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine
“The commencement of this Phase II study represents an important milestone in the clinical development of our VE Patch technology and in the partnership with HHS for use of our technology in providing potentially improved Pandemic Influenza vaccines“ stated Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA. “The recent H1N1 influenza situation certainly highlights again the important global public health need in this arena. If we achieve our goal to achieve full protection with only a single dose plus patch this means an enormous logistical advantage making PanFlu immunization feasible”.
The H5N1 pandemic influenza vaccine tested in the study comprises Intercell’s VE Patch and an injectable H5N1 influenza vaccine manufactured by Solvay Biologicals, B.V. (Netherlands).
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.